source
- Dr Postow on the Timing of Delayed or Re-Emergent irAEs in MelanomaMichael A. Postow, MD, discusses the evolving understanding of ICIs in melanoma and the unique toxicity profiles associated with these agents.onclive · 3mo ago↗ source
- FDA chief Marty Makary resigns from agency, ending tumultuous tenureMakary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with drugmakers.BioPharma Dive · 3mo ago↗ source
- Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drugA deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.BioPharma Dive · 3mo ago↗ source